Defence Therapeutics has enhanced its internal capabilities in purification, analytical characterization, conjugation development, and quality control to advance its ACCUM-enabled Antibody Drug Conjugates (ADC) pipeline. The company acquired new equipment and improved workflows to ensure consistent, high-quality ADC candidates, supporting its partnership programs. These upgrades aim to speed up candidate selection and validation, positioning Defence as a leader in ADC development and manufacturing. The company expects these improvements to accelerate the creation of more effective cancer therapies with reduced side effects.
U-BX Technology's stock fell 15.6% in after-hours trading following the announcement of a 1-for-25 reverse stock split effective Friday. The move will reduce the number of outstanding shares significantly to maintain Nasdaq listing compliance. The co...
U.S. spot Bitcoin ETFs experienced $648.64 million in net outflows on May 18, following $290.42 million outflows on May 15, indicating a short-term defensive shift among institutional investors. BlackRock's IBIT fund led the withdrawals with $448.36 ...
Kornit Digital reported first quarter results that exceeded analyst expectations and provided a Q2 revenue forecast above estimates, signaling strong sales momentum. However, gross margins fell to a two-year low due to tariffs, currency challenges, a...
American Pacific Mining has begun a field reconnaissance and surface sampling program at its Red Hill Gold Project in Nevada to enhance geological understanding and gather geochemical data. Early findings include a significant jasperoid outcrop with ...
The Czech National Library of Technology has chosen Clarivate to implement a new cloud-based library services and discovery platform under a ten-year agreement. This platform, built on Clarivate's Alma and Primo systems, aims to modernize academic an...
